WARRINGTON, Pa., May 17, 2010 (GLOBE NEWSWIRE) -- Discovery Laboratories, Inc. (Nasdaq:DSCO) announced that data from a preclinical study using Discovery Labs’ KL4 surfactant (lucinactant) in an established porcine model of lung transplantation demonstrated a potentially important protective role in a newly transplanted lung, reducing ischemia-reperfusion injury often seen after lung transplantation . These data were presented at the 2010 American Thoracic Society International Conference, which is internationally recognized as the most important medical congress dedicated to advancement of the clinical and scientific understanding of pulmonary medicine. The study is summarized below:
